Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells
- PMID: 19919653
- DOI: 10.1111/j.1365-2141.2009.07980.x
Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells
Abstract
Osteolytic lesions are a hallmark of multiple myeloma. They are due to the hyperactivity of bone resorbing osteoclasts and hypoactivity of bone forming osteoblasts, in response to neighbouring myeloma cells. This study identified a structure that deeply affects this response, because of its impact on the physical organisation of the myeloma cell microenvironment. The proximity between myeloma cells and osteoclasts or osteoblasts was shown to be conditioned by the recently discovered layer of flat cells that separates the osteoclasts and osteoblasts from the bone marrow, by forming a canopy over bone remodelling compartment (BRC). These canopies are frequently disrupted in myeloma, and this disruption correlates with increased proximity and density of myeloma cells. In vitro evidence indicates that this disruption may be due to direct contact between myeloma and BRC canopy cells. Importantly, this disruption and increased proximity and density of myeloma cells coincides with key myeloma-induced bone events, such as osteolytic lesions, impaired bone formation despite increased bone resorption, and fusion of myeloma cells with osteoclasts thereby forming myeloma-osteoclast hybrid cells. These findings strongly support a critical role of BRC canopies in myeloma-induced bone disease. BRC canopies could therefore be considered as a new therapeutic target.
Similar articles
-
Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.Dan Med Bull. 2011 May;58(5):B4277. Dan Med Bull. 2011. PMID: 21535989 Review.
-
Pathophysiology of multiple myeloma bone disease.Hematol Oncol Clin North Am. 2007 Dec;21(6):1035-49, viii. doi: 10.1016/j.hoc.2007.08.009. Hematol Oncol Clin North Am. 2007. PMID: 17996587 Review.
-
Pathogenesis of myeloma bone disease.Blood Cells Mol Dis. 2004 Mar-Apr;32(2):290-2. doi: 10.1016/j.bcmd.2004.01.001. Blood Cells Mol Dis. 2004. PMID: 15003820 Review.
-
Pathogenesis of myeloma bone disease.J Cell Biochem. 2010 Feb 1;109(2):283-91. doi: 10.1002/jcb.22403. J Cell Biochem. 2010. PMID: 20014067
-
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.J Bone Miner Res. 2009 Mar;24(3):425-36. doi: 10.1359/jbmr.081104. J Bone Miner Res. 2009. PMID: 19016584
Cited by
-
Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.Bone. 2015 Jun;75:161-9. doi: 10.1016/j.bone.2015.02.021. Epub 2015 Feb 26. Bone. 2015. PMID: 25725265 Free PMC article. Review.
-
Multiple Myeloma Associated Bone Disease.Cancers (Basel). 2020 Jul 30;12(8):2113. doi: 10.3390/cancers12082113. Cancers (Basel). 2020. PMID: 32751464 Free PMC article. Review.
-
Bone metastasis: the importance of the neighbourhood.Nat Rev Cancer. 2016 May 25;16(6):373-86. doi: 10.1038/nrc.2016.44. Nat Rev Cancer. 2016. PMID: 27220481 Review.
-
Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma.Curr Oncol. 2022 Dec 5;29(12):9535-9549. doi: 10.3390/curroncol29120749. Curr Oncol. 2022. PMID: 36547163 Free PMC article. Review.
-
Myeloma Bone Disease: A Comprehensive Review.Int J Mol Sci. 2021 Jun 8;22(12):6208. doi: 10.3390/ijms22126208. Int J Mol Sci. 2021. PMID: 34201396 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical